

**For Immediate Release**

**Q2 Net Revenue at Rs 789 Crores, Net Profit at Rs 120 Crores**

**Vadodara November 7<sup>th</sup>, 2017**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter ending 30<sup>th</sup> September 2017.

**Q2 FY18 Financial Highlights**

- Net Revenue at Rs 789 crores against Rs 879 crores last year.
- EBITDA margin at 23% against 20% last year
- Net Profit at Rs 120 crores against Rs 119 crores last year.

**Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited** said “The US formulations business continues to face price erosion on some key products, however the India branded business is showing signs of recovery. We recently concluded the acquisition of Orit Laboratories LLC which will strengthen our presence in the US market.”

**Operational Highlights for the quarter**

**International Business**

- International formulation business revenue at Rs 262 crores against Rs 352 crores.
- US formulation business revenue was Rs 190 crores against Rs 269 crores.
- 4 ANDA approvals received during the quarter, Cumulative ANDA approvals at 62
- 3 ANDA filings during the quarter, Cumulative ANDA filings at 104
- R&D Spend at Rs 98 crores (12% of Net revenue) against Rs 112 crores (13% of Net revenue) last year

**India Formulations Business**

- India formulations business for the quarter grew by 6% at Rs 385 crores as against Rs 363 crores last year, though the numbers are not strictly comparable due to GST treatment.

**ALEMBIC PHARMACEUTICALS LIMITED**

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q2 FY18	Q2 FY17	% Change	H1 FY18	H1 FY17	% Change
<b>Formulations</b>						
International	262	352	-26%	543	660	-18%
India	385	363	6%	621	663	-6%
<b>API</b>	142	164	-13%	273	293	-7%
<b>Total</b>	<b>789</b>	<b>879</b>	<b>-10%</b>	<b>1,437</b>	<b>1,616</b>	<b>-11%</b>

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q2 FY18	Q2 FY17	% Change	H1 FY18	H1 FY17	% Change
EBITDA Pre R&D	273	286	-5%	465	523	-11%
<i>EBITDA Pre R&amp;D %</i>	<i>35%</i>	<i>33%</i>		<i>32%</i>	<i>32%</i>	
EBITDA Post R&D	179	178	1%	281	335	-16%
<i>EBITDA Post R&amp;D %</i>	<i>23%</i>	<i>20%</i>		<i>20%</i>	<i>21%</i>	
Profit Before Tax	161	157	3%	240	294	-18%
Net Profit after Tax	120	119	1%	186	221	-16%

#### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

#### **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
 website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

**For more information contact:**

<b>Ajay Kumar Desai</b>  Phone: +91 22 – 306 11681  Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	<b>Mitanshu Shah</b>  Phone: +91 265 – 3007630  Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>
---	---

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123